Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes TranscriptSeeking Alpha • 09/22/26
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a monthMarket Watch • 09/22/26
Viking Therapeutics shares surge over 27% on weight loss drug maintenance dataProactive Investors • 09/22/26
Viking Therapeutics' VK2735 Shows Strong Weight-Loss Retention With Monthly DosingMarketBeat • 09/22/26
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent DosingBenzinga • 09/22/26
Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.Barrons • 09/22/26
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.Investors Business Daily • 09/22/26
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing RegimensPRNewsWire • 09/22/26
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher24/7 Wall Street • 09/21/26
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?Zacks Investment Research • 09/17/26
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.The Motley Fool • 09/17/26
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 09/16/26
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight LossMarketBeat • 09/15/26
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?Zacks Investment Research • 09/11/26
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 09/10/26
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/10/26
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.The Motley Fool • 09/10/26